Does SWB issue lot-specific documentation, or a batch certificate?

This is my second independent submission on material from the same supplier.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Reconciling gross mass to label claim

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

To be exact about it, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

In practice, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

It helps to be literal here: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.